Standard BioTools Reports Third-Quarter Revenue of $19.4 Million
Standard BioTools reported third-quarter 2026 net income of $13.5 million and diluted EPS of $0.03, compared with a $34.7 million net loss and a $0.09 diluted loss per share a year earlier. Revenue fell 0.9% from $19.6 million. Current-quarter results included $28.5 million of income from discont…
Standard BioTools reported third-quarter 2026 revenue of $19.4M, down 0.9% from $19.6M a year earlier. Net income was $13.5M, compared with a $34.7M net loss in the prior-year quarter, while diluted EPS was $0.03 versus a loss of $0.09; current-quarter results included $28.5M of income from discont…